Therapeutics News and Research

RSS

Treat discomfort not fever say the new pediatric guidelines

According to a new report from the American Academy of Pediatrics (AAP), fevers alone are not a cause for intervention in children. Dr. Janice Sullivan, the lead author of the report says, “The focus should be on comfort and not on absolute temperature.” That’s because fever can be help fight illness, by slowing down the reproduction of bacteria and viruses or stimulating the body’s immune response she explains. “That’s a benefit of fever…and may shorten the time that your child remains ill,” she adds.

28 Feb 2011

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.

28 Feb 2011

Cryo-Cell fiscal 2010 net income increases to $3.4 million

Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks and an industry leader of innovative stem cell solutions, today announced results for its fiscal year 2010.

28 Feb 2011

BrainStorm raises $3.6 million through private placement financing

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing in reliance upon Regulation S. BrainStorm received gross proceeds of approximately $3.6 million resulting from the sale of shares at a purchase price of $0.28 per share at the closing of the transaction.

28 Feb 2011

Synageva supports Fourth International Rare Disease Day

Synageva BioPharma Corp., a privately held biopharmaceutical company that is developing therapeutic products for rare disorders, announced today that the company is supporting the Fourth International Rare Disease Day observance on February 28, 2011.

28 Feb 2011

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.

28 Feb 2011

Positive results from Trius torezolid Phase 1 lung study

Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into the lung for potential use to treat lung infections. In this study a 200 mg dose of torezolid phosphate was administered orally once-daily for three days to healthy adult volunteers. The trial achieved its primary goal of establishing the steady-state plasma pharmacokinetics and distribution of active drug into epithelial lining fluid (ELF).

28 Feb 2011

Arsanis closes Series A financing for $10 million

Arsanis, Inc, a recently founded biotechnology company dedicated to the development of anti-infective monoclonal antibody therapeutics, today announced the closing of a Series A financing with a total funding amount of $10 million. Proceeds from the initial financing will be used to advance several programs in the anti-microbial infectious disease area.

28 Feb 2011

Despite FDA action, Deston still believes Auralgan as a safe and effective drug product

Deston Therapeutics LLC announced today that it is currently exploring its options to respond to a recent seizure of its Auralgan Otic Solution by the Federal Government and that it still believes that Auralgan is a safe and effective drug product.

28 Feb 2011

Affymetrix introduces new GeneChip miRNA 2.0 Array

Affymetrix, Inc. today launched the GeneChip miRNA 2.0 Array. This enhanced version of its best-in-class microRNA interrogation solution will support the research community's pursuit of personalized medicine by accelerating the identification of biomarkers and gene expression signatures associated with disease.

28 Feb 2011

Selcia completes drug discovery project with ExonHit Therapeutics using fragment screening technology

Selcia Ltd today announced the successful completion of a drug discovery project with ExonHit Therapeutics SA, using Selcia's fragment screening technology. Novel and weak affinity hits were identified from Selcia's Fragment Library, using their proprietary CEfrag technique.

28 Feb 2011

FUJIFILM enters definitive agreement to acquire Merck

FUJIFILM Corporation and Merck, known as MSD outside the United States and Canada, today announced they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceutical industry and wholly owned by Merck.

28 Feb 2011

Targets against MRSA in microgravity

NASA astronauts onboard Space Shuttle Discovery's final mission to the International Space Station (ISS) will carry out the eleventh scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. The research on STS-133 will focus on changes that occur to methicillin-resistant Staphylococcus aureus (MRSA) in microgravity, which can be targeted to create new vaccines and therapeutics.

25 Feb 2011

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

Signal files complaint against Med Biogene and Precision Therapeutics in Supreme Court

Med Biogene Inc., a Vancouver-based life sciences company, has been charged with fraud, and Pittsburgh-based Precision Therapeutics, Inc., was charged with tortious interference in an amended complaint filed today by Signal Genetics in Supreme Court for the County of New York.

25 Feb 2011

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.

25 Feb 2011

Therapeutics News and Research

Treat discomfort not fever say the new pediatric guidelines

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

Cryo-Cell fiscal 2010 net income increases to $3.4 million

BrainStorm raises $3.6 million through private placement financing

Synageva supports Fourth International Rare Disease Day

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Positive results from Trius torezolid Phase 1 lung study

Arsanis closes Series A financing for $10 million

Despite FDA action, Deston still believes Auralgan as a safe and effective drug product

Affymetrix introduces new GeneChip miRNA 2.0 Array

Selcia completes drug discovery project with ExonHit Therapeutics using fragment screening technology

FUJIFILM enters definitive agreement to acquire Merck

Targets against MRSA in microgravity

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Signal files complaint against Med Biogene and Precision Therapeutics in Supreme Court

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

ImmunoCellular to receive gross proceeds of $8.1M from sale of 5.2M units

UBC study shows Canadians and Americans receive different drug information online

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News